Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2fluorodopa F 18 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1pasireotide 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Surgical Procedures, Operative 1Streptozocin 1Sorafenib 1Solutions 1Salts 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Insulinoma × batifiban × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡